Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02YFZ
|
||||
| Former ID |
DNC011916
|
||||
| Drug Name |
2-Piperazin-1-yl-benzonitrile
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C11H13N3
|
||||
| Canonical SMILES |
C1CN(CCN1)C2=CC=CC=C2C#N
|
||||
| InChI |
1S/C11H13N3/c12-9-10-3-1-2-4-11(10)14-7-5-13-6-8-14/h1-4,13H,5-8H2
|
||||
| InChIKey |
FRICBZWJFIRJOB-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 1A receptor | Target Info | Inhibitor | [1] | |
| 5-hydroxytryptamine 1D receptor | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapsehsa04024:cAMP signaling pathway | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| 5HT1 type receptor mediated signaling pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | J Med Chem. 1989 May;32(5):1052-6.Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.